---
title: "Anagrelide - Essential thrombocythemia"
sidebar: mydoc_sidebar
permalink: db00261-mesh-d013920-1.html
toc: false 
---


Path ID: `DB00261_MESH_D013920_1`
{% include image.html url="images/db00261-mesh-d013920-1.png" file="db00261-mesh-d013920-1.png" alt="db00261-mesh-d013920-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| MESH:C021139 | Anagrelid | Drug |
| GO:0035855 | Megakaryocyte development | BiologicalProcess |
| GO:0030220 | Platelet formation | BiologicalProcess |
| HP:0001894 | Thrombocytosis | PhenotypicFeature |
| MESH:D013920 | Essential thrombocythemia | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Anagrelid | NEGATIVELY REGULATES | Megakaryocyte Development |
| Megakaryocyte Development | POSITIVELY CORRELATED WITH | Platelet Formation |
| Platelet Formation | POSITIVELY CORRELATED WITH | Thrombocytosis |
| Thrombocytosis | MANIFESTATION OF | Essential Thrombocythemia |
|---------|-----------|---------|

Comment: the exact mechanism by which anagrelide lowers platelet count is unclear

Reference: [https://go.drugbank.com/drugs/DB00261#mechanism-of-action](https://go.drugbank.com/drugs/DB00261#mechanism-of-action){:target="_blank"}